Compared with path_MLH1 and path_MSH2 carriers, we found that path_MSH6 carriers had a lower risk of early-onset cancer and a lower risk of late-onset cancer in addition to an intermediate risk of urinary tract or prostate cancer [45]. Here, MSH6 is linked to prostate cancer.